自身免疫性疾病史与上皮性卵巢癌长期生存:Extreme研究
基于丹麦1990-2014年诊断为上皮性卵巢癌的11870例女性,采用全国登记数据,用伪值法估计合并自身免疫病及四种常见自身免疫病的5年和10年绝对与相对生存概率。合并自身免疫病与生存无显著关联,但分层后局限期上皮性卵巢癌合并自身免疫病者10年相对生存概率降低。
要点
- 合并自身免疫病与上皮性卵巢癌总体生存无显著关联。
- 局限期上皮性卵巢癌合并自身免疫病者10年相对生存概率降低。
- 四种常见自身免疫病均与上皮性卵巢癌生存无统计学显著关联。
核心结论
- 仅在局限期上皮性卵巢癌女性中,自身免疫性疾病史似乎与长期生存损失相关。
- 在非局限期上皮性卵巢癌女性中,自身免疫性疾病史与生存无显著关联,该人群生存率本已较低。
研究设计与样本
- Extreme研究纳入丹麦1990-2014年诊断为上皮性卵巢癌的女性,共11870例。
- 暴露与协变量信息来自全国登记系统,采用伪值法估计5年和10年绝对及相对生存概率及95%CI。
主要发现
- 无自身免疫病的上皮性卵巢癌女性总体5年和10年绝对生存概率分别为35%和24%。
- 合并自身免疫病与上皮性卵巢癌生存无显著关联:5年调整相对生存概率=1.01(95%CI:0.94-1.09),10年调整相对生存概率=0.90(95%CI:0.81-1.00)。
- 按疾病分期分层后,合并自身免疫病且为局限期上皮性卵巢癌的女性10年相对生存概率=0.86(95%CI:0.76-0.97)。
- 四种常见自身免疫病(1型糖尿病、类风湿关节炎、Graves病、炎症性肠病)均与上皮性卵巢癌生存无统计学显著关联。
关键数值与推荐
- 无自身免疫病的上皮性卵巢癌女性5年绝对生存概率为35%,10年绝对生存概率为24%。
- 合并自身免疫病与上皮性卵巢癌生存无显著关联:5年调整相对生存概率=1.01(95%CI:0.94-1.09),10年调整相对生存概率=0.90(95%CI:0.81-1.00)。
- 合并自身免疫病且为局限期上皮性卵巢癌的女性10年相对生存概率=0.86(95%CI:0.76-0.97)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with autoimmune disease may have impaired cancer survival. The aim was to investigate the association between autoimmune disease and ovarian cancer survival. METHODS: From the Extreme study, we included women diagnosed with epithelial ovarian cancer (EOC) in Denmark during 1990-2014 (n = 11,870). Information on exposure and covariates was retrieved from nationwide registries. Using pseudo-values, we estimated absolute and relative 5- and 10-year survival probabilities with 95% confidence intervals (CIs) for autoimmune diseases combined and for the four most common individual disorders in our study population, namely type 1 diabetes, rheumatoid arthritis, Graves' disease, and inflammatory bowel disease. RESULTS: The overall 5- and 10-year absolute survival probabilities were 35% and 24%, respectively, in women with EOC without autoimmune disease. Autoimmune diseases combined was not significantly associated with survival among women with EOC (5-year adjusted relative survival probability = 1.01, 95% CI: 0.94-1.09; 10-year adjusted relative survival probability = 0.90, 95% CI: 0.81-1.00). However, stratification by disease stage showed an impaired 10-year survival in women with autoimmune disease and a localized EOC (relative survival probability = 0.86, 95% CI: 0.76-0.97). None of the individual autoimmune diseases were statistically significantly associated with EOC survival. CONCLUSIONS: Only among women with localized EOC, there seemed to be a long-term survival loss associated with a history of autoimmune disease. In contrast, no significant association between a history of autoimmune disease and survival was observed in women with nonlocalized EOC where the survival is already low.
引用
- Hannibal CG, Kjaer SK, Galanakis M, et al. History of autoimmune disease and long-term survival of epithelial ovarian cancer: The extreme study. Gynecol Oncol. 2024. PMID: 38246041. doi:10.1016/j.ygyno.2023.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。